Nuclear medicine – Ushering in a new era of healthcare innovation

The expanding scope of nuclear medicine beyond oncology into cardiovascular, neurological, and musculoskeletal disorders breaks insurmountable barriers holding great promise.

Nuclear medicine is revolutionizing healthcare by fusing advanced imaging with therapeutic techniques to deliver precision and personalized care. By using radiopharmaceuticals to diagnose and treat diseases, this branch of radiography enables detecting and managing a wide range of conditions, particularly non-communicable diseases. A small amount of radioactive substance is injected into the patient, collaborating with imaging technology, to create detailed visuals of the body. While seemingly daunting, this technique is safe, as the radioactivity diminishes to undetectable levels within days.

Among the most widely used nuclear medicine techniques are PET (positron emission tomography) scans, often combined with CT and MRI to generate 3D images of organs. These scans are crucial for detecting early signs of cancer, diagnosing neurological disorders, and assessing cardiovascular health with exceptional accuracy. With its growing role in disease management, nuclear medicine is propelling healthcare into a new era, shaping how conditions, such as heart disease, gastrointestinal disorders, and cancer, are diagnosed, treated, and monitored.

Nuclear medicine has transformed the landscape of medical diagnostics through cutting-edge equipment like gamma cameras, PET scanners, and SPECT scanners. These technologies offer unique insights into the human body’s inner workings, playing a pivotal role in diagnosing and treating a range of diseases.

Gamma cameras capture real-time images by detecting gamma rays emitted by radiopharmaceuticals injected into the patient. This technology is widely used for thyroid scans, bone scintigraphy, and cardiac imaging, helping clinicians detect abnormalities and track disease progression with precision.

PET scanners unveil metabolic activity by capturing gamma photons produced during positron-electron interactions in the body. This capability is essential in oncology, neurology, and cardiology, where PET helps detect cancers, Alzheimer’s disease, and cardiac conditions early. Its strength lies in visualizing cellular processes, making it a powerful tool for diagnosis and treatment planning.

SPECT further enhances imaging capabilities by rotating around the patient and measuring gamma rays emitted from radioactive substances. SPECT excels in mapping blood flow and evaluating organ function, making it crucial for diagnosing coronary artery disease, strokes, and seizure disorders.

Beyond diagnostics, these technologies also play a critical role in treatment. For instance, in targeted radiotherapy, radiopharmaceuticals deliver therapeutic doses of radiation directly to cancer cells, sparing healthy tissue. This dual application of precise diagnosis and targeted treatment is reshaping patient care.

Indian market dynamics
The Indian market for nuclear medicine equipment in 2023 is estimated at ₹671 crore with 83 units.

PET scanners continue to dominate the market, accounting for 92 percent of the share in 2023, by value. AIIMS procured the scanners for its hospitals across India, as did the Central Armed Police Forces Institute of Medical Science, Safdarjung Hospital, and other government hospitals. HLL Lifecare invited the bids. These purchases are continuing in 2024.

With the advent of fast scintillator detectors with lutetium oxy orthosilicate (LSO) crystals, true time of flight (TOF) has become a realistic innovation for the clinical setting in large corporate hospitals. LSO-based TOF offers numerous advantages such as better definition of small lesions, improved uniformity, reduced noise, and sensitivity gain. The fast LSO crystals and optimized electronics are designed to convert the analog signal from the crystals into a digital signal that allows measurement of the TOF resolution.

On the other hand, the high cost of purchasing and operating PET scanners becomes a significant barrier for hospitals with limited budgets. Moreover, they require ongoing maintenance, calibration, and repair, as well as specialized personnel to operate and interpret the results, which leads to additional ongoing costs that can be significant, and accumulate over time.

The single-photon emission computed tomography (SPECT) segment continues to meet niche demand, with its multiple uses for endocrine, thyroid, ortho, cardiology, neurology, and oncology. It accounted for 8 percent by value and 22 percent by units.

No cyclotrons were sold in 2023.

Chronic diseases are a significant public health concern in India, with cardiovascular diseases, diabetes, respiratory diseases, cancer, and mental health disorders among the top concerns. Before now, PET scans were primarily employed in diagnosing and staging cancer. Many medical disciplines are now incorporating PET scans into their diagnostic methods as their applications grow outside cancer. As a result, manufacturers and suppliers of PET scans attract new clients, boosting market demand. For example, in cardiology, PET scans are used to measure heart blood flow, pinpoint areas of damage, and gauge how well heart failure medications work. In the field of neurology, PET scans are used to diagnose and track illnesses, including migraine and seizures, as well as neurodegenerative diseases like Parkinson’s and Alzheimer’s. PET scans are also being researched for use in organ transplant rejection assessment, therapy response assessment, and identification of autoimmune diseases. Thus, a significant factor propelling market expansion is the growing range of uses for PET scans outside of cancer diagnosis.

Moreover, the expansion of nuclear medicine equipment in Indian hospitals is driven by significant government initiatives and investments. As part of efforts to boost energy security and healthcare advancements, the Indian government is promoting nuclear technology for medical purposes, including diagnostics and treatment. One key focus is increasing the production of medical isotopes essential for nuclear imaging and cancer treatment.

In support of this, India has launched a public-private partnership (PPP) model to enhance the production of medical isotopes. This initiative is expected to expand the availability of nuclear medicine, facilitating treatments for cancer and other diseases. Additionally, India is developing its capacity for theranostics, which combines diagnostics and therapy using radioactive substances. It shows promise for cancer treatment and early diagnosis of conditions like Alzheimer’s disease.

Furthermore, the development of indigenous technology and increased collaboration among public and private sectors are streamlining the production and deployment of nuclear medicine equipment.

Collaborations and partnerships between Indian institutions and global companies are also pivotal in advancing nuclear medicine. These partnerships focus on enhancing the production of medical isotopes, which are crucial for diagnostic imaging and cancer treatment. Public-private partnerships, like those with the Department of Atomic Energy, aim to boost isotope production for clinical use, supporting the growth of nuclear imaging technologies.

Additionally, collaborations with global companies drive innovation in nuclear medicine equipment, including cyclotrons and PET/CT scanners, improving access to precision care in Indian hospitals. These efforts are helping to integrate cutting-edge technologies and expand nuclear medicine’s reach across the country, improving patient care and promoting health outcomes.

Global market scenario
The global nuclear medicine market is valued at USD 10.19 billion in 2024, and is expected to reach USD 42.03 billion by 2032, at a CAGR of 19.4 percent.

The rising prevalence of cancers and cardiovascular and neurological diseases worldwide is driving the need for more effective therapeutic and diagnostic products, which are expected to enhance patient treatment outcomes. This growing demand is likely to boost the adoption of these products during the forecast period. Additionally, to strengthen radiopharmaceutical supply chains, positive initiatives by various stakeholders, including governments and agencies like the International Atomic Energy Agency (IAEA), are expected to contribute significantly to market growth. Furthermore, market players focus on strategic collaborations and new product launches, which are anticipated to propel the market in the coming years further.

Additionally, both established and emerging market players are actively launching diagnostic products. Many prominent global leaders have also entered into agreements and partnerships for the development and commercial release of diagnostic radiopharmaceuticals, which is expected to boost the market further.

In 2023, the dominant region was North America, which generated a revenue of USD 4.63 billion. The area is expected to dominate the global market due to its vital innovation, adoption of radiopharmaceuticals, rising chronic disease prevalence, and favorable reimbursement trends. Europe has been identified as the second-most dominant region in the market. It is anticipated that significant growth trends will be witnessed due to several prominent market players in the region. The Asia-Pacific market is expected to witness the highest CAGR over the next five years.

Ionizing radiation
Ionizing radiation is a cornerstone of nuclear medicine, revolutionizing both diagnosis and therapy. By harnessing the energy from ionizing radiation, nuclear medicine techniques offer a non-invasive, precise way to view and treat the body’s inner workings.

In diagnosis, radiopharmaceuticals containing small amounts of radioactive materials are introduced into the body, emitting ionizing radiation. Imaging devices, including gamma cameras and PET and SPECT scanners detect this radiation, which captures detailed images of the body’s organs, tissues, and cellular functions. The real-time feedback and high-resolution imagery allow for more accurate diagnosis, disease monitoring, and assessment of treatment effectiveness.

Ionizing radiation takes a more targeted approach in therapy. Radiotherapy uses ionizing radiation to destroy cancer cells while minimizing damage to surrounding healthy tissues. By delivering precise radiation doses directly to tumors, this method effectively treats cancers, including thyroid, prostate, and certain types of brain and bone cancers.

The benefits of using ionizing radiation in nuclear medicine extend beyond its precision. It allows for earlier detection of diseases, leading to faster interventions and better patient outcomes. Moreover, its ability to provide diagnostic and therapeutic capabilities within the same framework makes it invaluable for personalized medicine, ensuring that treatment is tailored to the patient’s needs.

Moreover, radiopharmaceuticals play a crucial role in nuclear medicine’s diagnostic and therapeutic applications. By combining radioactive isotopes with pharmaceutical compounds, these agents offer precise targeting for both imaging and treatment. For example, radiolabelled tracers like Technetium-99m are used in imaging techniques, such as PET and SPECT scans, providing detailed insights into organ function and abnormalities.

On the therapeutic side, radiopharmaceuticals, such as Iodine-131, are instrumental in treating diseases like thyroid cancer by delivering targeted radiation that eradicates malignant cells while sparing surrounding healthy tissue. This approach’s precision minimizes side effects and maximizes therapeutic efficacy, making radiopharmaceuticals a powerful tool in personalized medicine.

Innovative developments in radiopharmaceuticals also include advanced delivery systems, such as passive targeting through enhanced permeability and retention (EPR) and active targeting using ligand-receptor interactions. These strategies ensure that radiopharmaceuticals reach specific diseased tissues, improving the effectiveness of both diagnosis and therapy.

Additionally, the emergence of nanoparticle-based formulations is transforming next-generation radiopharmaceuticals. These cutting-edge innovations enable more controlled and precise drug delivery, improving therapeutic outcomes. Nanoparticles can enhance the delivery of radiopharmaceuticals to tumors and other targeted areas, reducing toxicity and improving patient safety.

Radiopharmaceuticals also shine in the realm of theranostics, where they serve a dual role in diagnosing and treating diseases. This integration allows for image-guided treatments, ensuring real-time monitoring of therapeutic progress and adjusting interventions as needed. The safety profile of radiopharmaceuticals has significantly improved, with ongoing research focusing on minimizing side effects and optimizing radiation dose management.

As radiopharmaceutical technologies evolve, they become increasingly aligned with artificial intelligence (AI) advances. AI improves diagnostic accuracy and treatment planning by analyzing vast datasets to detect subtle patterns and predict treatment outcomes. This combination of AI and radiopharmaceuticals represents the future of precision medicine, where each patient’s unique molecular profile guides personalized treatment strategies for improved outcomes.

In the evolving landscape of nuclear medicine, AI and radiomics are emerging as transformative forces, redefining how medical imaging equipment is utilized and how diagnoses and treatments are approached.

Artificial intelligence is revolutionizing nuclear medicine by enhancing the capabilities of imaging technologies and diagnostic tools. AI algorithms are adept at processing and analyzing large datasets generated from nuclear medicine imaging techniques. They can identify subtle patterns and anomalies that might escape human detection, improving diagnostic accuracy and enabling earlier disease detection. AI’s role extends to optimizing imaging protocols, assisting in precise treatment planning, and evaluating patient responses in real time. Integrating AI into nuclear medicine workflows allows healthcare professionals to achieve more personalized and effective patient care, significantly advancing diagnostic and therapeutic outcomes.

Radiomics, on the other hand, delves into the extraction and analysis of quantitative data from medical images and focuses on deriving detailed features from imaging studies, such as texture, shape, and intensity, which can provide deeper insights into disease characteristics and progression. Radiomics transforms imaging data into actionable information, aiding in predicting patient outcomes and tailoring treatment plans. When combined with AI, radiomics can offer enhanced capabilities for interpreting complex imaging data, leading to more precise and individualized care.

AI and radiomics are reshaping nuclear medicine by bridging the gap between advanced imaging technologies and clinical decision making. AI algorithms leverage radiomics data to refine diagnostic accuracy and treatment strategies, making personalized medicine a reality. As these technologies evolve, they promise to improve patient outcomes through more precise, data-driven disease diagnosis and management approaches.

Challenges in the adoption of nuclear medicine equipment
Economic and operational factors significantly impact the field of nuclear medicine equipment. The high costs associated with the procurement, maintenance, and operation of sophisticated imaging technologies, such as PET and SPECT scanners, can be a substantial barrier. The initial investment in these advanced systems and ongoing operational expenses affect healthcare budgets and resource allocation.

Economic considerations include the cost of radioactive isotopes, which are crucial for imaging and therapeutic procedures. The production and supply of these isotopes involve complex processes and specialized facilities, contributing to their high price. Additionally, the cost-effectiveness of nuclear medicine procedures is influenced by the need for precise and timely delivery of radiopharmaceuticals, which can impact supply chain issues and production inefficiencies.

Operational challenges encompass the need for skilled personnel to operate and interpret nuclear medicine equipment results. Regular maintenance and calibration of imaging systems are essential to ensure accuracy and reliability, adding to operational costs. The integration of new technologies, such as AI and radionics, also demands continuous training and adaptation from healthcare professionals.

Expansion of nuclear medicine in non-oncological applications
Nuclear medicine, traditionally known for its pivotal role in cancer diagnosis and treatment, is expanding its scope into non-oncological areas. One notable advancement is in musculoskeletal (MSK) infections, where radionuclide imaging, such as PET/CT and SPECT/CT, has become a critical tool for diagnosing conditions like osteomyelitis and prosthetic joint infections. These hybrid imaging techniques provide detailed insights into inflammation and infection, helping to monitor treatment responses effectively.

Beyond MSK infections, nuclear medicine is gaining traction in cardiovascular and neurological disorders. It plays a key role in diagnosing and managing diseases like coronary artery disease, Alzheimer’s, and Parkinson’s. New radiopharmaceuticals and innovative imaging technologies are enhancing its diagnostic accuracy, while machine learning is opening doors for more standardized and efficient use in non-oncological healthcare settings. This growing field promises to improve patient outcomes across various medical conditions.

Outlook
Nuclear medicine is revolutionizing healthcare by combining precision diagnostics with targeted therapies, making it a cornerstone in the fight against a wide range of diseases. Its expanding scope beyond oncology into cardiovascular, neurological, and musculoskeletal disorders showcases its versatility and potential. With advancements in radiopharmaceuticals, AI integration, and global market growth, nuclear medicine continues to break barriers in personalized care, improving patient outcomes. As technology evolves and becomes more accessible worldwide, nuclear medicine promises a future where diseases are detected earlier, treated more effectively, and managed with unparalleled precision – ushering in a new era of healthcare innovation.

SECOND OPINION

Emerging role of total-body PET/CT with artificial intelligence